Search Results
Your search for AT matches 29067 pages
Showing 11801 - 11850Study Links Sustained Weight Loss to Reduced Breast Cancer Risk
A new study finds that women who lost weight after age 50 and kept it off had a lower risk of breast cancer than women whose weight remained stable, helping answer a vexing question in cancer prevention.1 The reduction in risk increased with the amount of weight lost and was specific to women not...
FDA Approves Enzalutamide for Patients With Metastatic Castration-Sensitive Prostate Cancer
On December 16, the U.S. Food and Drug Administration (FDA) approved enzalutamide (Xtandi) for patients with metastatic castration-sensitive prostate cancer. The FDA previously approved enzalutamide for patients with castration-resistant prostate cancer. ARCHES Trial Efficacy was investigated in...
Lung Cancer Expert Julie R. Brahmer, MD, MSc, Was an Early Believer in Immunotherapy—and Still Is
Lung cancer specialist Julie R. Brahmer, MD, MSc, comes from a long line of Midwest farmers who still run a family operation. “I’m originally from what I would call the middle of nowhere in Nebraska. My father is a sixth-generation farmer, and my mother is a nurse. I was inclined toward medicine at ...
Immunotherapy for Head/Neck Squamous Cell Carcinoma: Questions Raised by KEYNOTE-048
There is a new first-line treatment option for patients with newly diagnosed, recurrent, or metastatic head and neck squamous cell carcinoma. As reported by Burtness et al in The Lancet, pembrolizumab improved overall survival vs the standard-of-care regimen of cetuximab and platinum-based...
TIVO-3: Third- or Fourth-Line Tivozanib vs Sorafenib in Metastatic Renal Cell Carcinoma
As reported in The Lancet Oncology by Brian I. Rini, MD, and colleagues, the phase III TIVO-3 trial has shown a statistically significant increase in progression-free survival with tivozanib vs sorafenib as a third- or fourth-line treatment for advanced renal cell carcinoma. Study Details The...
Evaluation of Residual Disease in Patients With Multiple Myeloma Using IMWG Flow Cytometry Criteria
In a study reported in the Journal of Clinical Oncology, Paiva et al examined the applicability of International Myeloma Working Group (IMWG) criteria for next-generation flow cytometry assessment of minimal residual disease (MRD) in multiple myeloma. They found that the IMWG flow MRD-negative...
ESMO Immuno-Oncology 2019: First-Line Immunotherapy Combination for Patients With Advanced NSCLC and Comorbidities or Poor Performance Status
First-line treatment with the combination of nivolumab and ipilimumab was safe and provided encouraging overall survival results in patients with advanced non–small cell lung cancer (NSCLC), as well as in patients with NSCLC traditionally not eligible for clinical trials—such as those who had...
ESMO Immuno-Oncology 2019: CXCR4 Inhibitor in Combination With Pembrolizumab/Chemotherapy for Metastatic Pancreatic Cancer
When the CXCR4 inhibitor BL-8040 was combined with the programmed cell death protein 1 (PD-1) inhibitor pembrolizumab plus chemotherapy in the second-line setting, the regimen showed promising antitumor activity in patients with metastatic pancreatic ductal adenocarcinoma. These findings were...
ESMO Immuno-Oncology 2019: Sitravatinib/Tislelizumab Shows Antitumor Activity in Ovarian Cancer
Results from a phase Ib study reported at the European Society for Medical Oncology (ESMO) Immuno-Oncology Congress 2019 showed manageable safety and encouraging antitumor activity in patients with advanced ovarian cancer treated with the novel combination of sitravatinib and tislelizumab. These...
Hongchao Pan, PhD, on an Update on 5 Years of Endocrine Therapy for Early Breast Cancer
Hongchao Pan, PhD, of the University of Oxford, discusses an analysis of 86,000 women in the Early Breast Cancer Trialists’ Collaborative Group database, which showed that the risk of distant recurrence 20 years after a diagnosis of node-negative, estrogen receptor–negative early-stage breast...
Ivana Sestak, PhD, on Clinical Treatment Score From TAILORx: Predicting Distant Breast Cancer Recurrence
Ivana Sestak, PhD, of Queen Mary University of London and the Centre for Cancer Prevention, discusses study findings that confirm the prognostic ability of the Clinical Treatment Score at 5 years (CTS5) for late distant recurrence, specifically for patients older than 50 years and/or for those...
Rowan T. Chlebowski, MD, PhD, on Breast Cancer: Findings From The Women’s Health Initiative
Rowan T. Chlebowski, MD, PhD, of the Lundquist Institute at Harbor-UCLA Medical Center, discusses the long-term influence of using estrogen plus progestin or estrogen alone on breast cancer incidence and mortality (Abstract GS5-00).
Madeleine M.A. Tilanus-Linthorst, MD, PhD, on MRI vs Mammography: Comparing Cost and Effectiveness
Madeleine M.A. Tilanus-Linthorst, MD, PhD, of Erasmus University, reports data from the first randomized trial comparing MRI breast cancer screening with mammography in women with a familial risk. Because MRI screening detected cancer at an earlier stage, it might reduce the use of adjuvant...
Joseph Sparano, MD: The William L. McGuire Memorial Lecture
Joseph Sparano, MD, of the Montefiore Medical Center, discusses three challenges: How can gene-expression profiles and other diagnostic tests be used to guide the use of adjuvant systemic therapy? Is it time to reappraise active surveillance? Are there diagnostic and therapeutic strategies that ...
Milan Radovich, PhD, on ctDNA After Neoadjuvant Chemotherapy and Recurrence in Triple-Negative Breast Cancer
Milan Radovich, PhD, of Indiana University School of Medicine, discusses trial findings that show patients with triple-negative breast cancer who are at high risk of relapse after receiving preoperative chemotherapy can be risk-stratified based on the presence of minimal residual disease as...
Plenary Presentations From the 2019 ASH Annual Meeting & Exposition
On this episode, we hear from the authors of three high-impact abstracts presented at the 2019 ASH Annual Meeting & Exposition. The first paper investigated immunotherapy vs standard chemotherapy for pediatric B-cell acute lymphoblastic leukemia; the second focused on the efficacy of oral...
SABCS 2019: Oral vs Intravenous Paclitaxel for Patients With Metastatic Breast Cancer
Patients with metastatic breast cancer who received an oral formulation of paclitaxel had better response and survival and less neuropathy than patients who received intravenous paclitaxel, according to results of a phase III trial presented at by Umanzor et al at the San Antonio Breast Cancer...
SABCS 2019: Residual Cancer Burden After Neoadjuvant Chemotherapy as a Predictive Tool
A large meta-analysis of patients with breast cancer showed that residual cancer burden after neoadjuvant chemotherapy is an accurate long-term predictor of recurrence and survival across all breast cancer subtypes, according to data presented by Yau et al at the 2019 San Antonio Breast Cancer...
SABCS 2019: Breast Cancer Incidence With Estrogen/Progestin vs Estrogen Alone in Postmenopausal Women
A study investigating the long-term influence of estrogen plus progestin compared with estrogen alone on breast cancer incidence in postmenopausal women has found that the menopausal hormone therapies had opposite effects on breast cancer incidence. While estrogen alone decreased breast cancer...
SABCS 2019: ctDNA May Be an Independent Predictor of Disease Recurrence in Patients With Early-Stage Triple-Negative Breast Cancer
The detection of circulating tumor DNA (ctDNA) in patients with early-stage triple-negative breast cancer treated with surgery following neoadjuvant chemotherapy is an independent predictor of disease recurrence, according to a phase II study investigating the potential of using ctDNA to detect...
Stephen Hahn, MD, Confirmed as FDA Commissioner by Senate
On December 12, the United States Senate voted 72–18 to confirm Stephen Hahn, MD, as Commissioner of the U.S. Food and Drug Administration (FDA). A radiation oncologist, Dr. Hahn was previously the Chief Medical Executive and Gilbert H. Fletcher Distinguished Memorial Chair and Professor of...
SABCS 2019: Does Treatment With Pembrolizumab Improve Pathologic Complete Response in Patients With Triple-Negative Breast Cancer and Lymph Node Involvement?
The addition of the checkpoint inhibitor pembrolizumab to neoadjuvant chemotherapy and as adjuvant therapy increased the rates of pathologic complete response in patients with triple-negative breast cancer who had lymph node involvement, according to results from the KEYNOTE-522 trial, which were...
SABCS 2019: 6-Year Analysis of the Addition of Pertuzumab to Trastuzumab Plus Chemotherapy as Adjuvant Therapy
Data from the 6-year analysis of the APHINITY trial showed that adding pertuzumab to the previous standard treatment of trastuzumab plus chemotherapy after surgery continued to reduce the risk of recurrence and death in patients with HER2-positive early breast cancer, according to findings...
SABCS 2019: 10-Year Follow-up of Adjuvant Accelerated Partial-Breast Irradiation vs Adjuvant Whole-Breast Irradiation
A 10-year follow-up study of patients with breast cancer who had been treated with accelerated partial-breast irradiation (APBI) after surgery showed that their rates of disease recurrence were similar to those of patients who had received whole-breast irradiation (WBI), according to data presented ...
SABCS 2019: Ribociclib/Letrozole vs Multiagent Chemotherapy in Patients With High-Risk Luminal B Breast Cancer
A phase II study by Gavilá et al evaluating the efficacy of the combination of the CDK4/6 inhibitor ribociclib and the aromatase inhibitor letrozole in combination as a neoadjuvant treatment in patients with high-risk luminal B breast cancer has found that the therapy produced response rates...
SABCS 2019: IBIS-II Study Finds Long-Term Preventive Benefit With Anastrozole Among Postmenopausal Women at High Risk for Breast Cancer
A 10-year median follow-up analysis of the IBIS-II trial on the efficacy and safety of the aromatase inhibitor anastrozole for healthy postmenopausal women at increased risk of developing breast cancer has found that the therapy reduced the likelihood of breast cancer incidence by 50% and had few...
Catherine M. Diefenbach, MD, on Follicular Lymphoma: Polatuzumab Vedotin Plus Obinutuzumab/Lenalidomide
Catherine M. Diefenbach, MD, of the Perlmutter Cancer Center at NYU Langone, discusses a primary analysis of a phase Ib/II trial showing that the novel triplet combination of polatuzumab vedotin plus obinutuzumab/lenalidomide is safe and effective, with high complete response rates seen in a...
SABCS 2019: Postoperative S-1 Plus Endocrine Therapy for HR-Positive, HER2-Negative Breast Cancer
The postoperative combination of S-1, an oral fluoropyrimidine-based drug, with endocrine therapy improved invasive disease–free survival and 5-year invasive disease–free survival estimates in patients with hormone receptor (HR)-positive, HER2-negative breast cancer, according to results from the...
SABCS 2019: Adding Tucatinib to Capecitabine/Trastuzumab Improved Survival for Patients With Advanced HER2-Positive Breast Cancer
The addition of tucatinib to capecitabine and trastuzumab significantly improved progression-free survival and overall survival in patients with advanced HER2-positive breast cancer, with or without brain metastasis. These findings—from the HER2CLIMB study—were presented by Murthy et al at the 2019 ...
SABCS 2019: [Fam-] Trastuzumab Deruxtecan in Patients With Pretreated HER2-Positive Metastatic Breast Cancer
A phase II clinical study investigating [fam-] trastuzumab deruxtecan (T-DXd) in patients with metastatic HER2-positive breast cancer previously treated with trastuzumab emtansine (T-DM1) showed patients had an overall response rate of 60.9% with the treatment. The study by Krop et al was presented ...
ASH 2019: Blinatumomab vs Standard Chemotherapy for Pediatric Patients With Relapsed B-ALL
Blinatumomab improved survival in children with relapsed B-acute lymphoblastic leukemia (B-ALL) compared with standard chemotherapy, accordings to findings from a study presented by Brown et al at the 2019 American Society of Hematology (ASH) Annual Meeting & Exposition (Abstract LBA-1)....
ASH 2019: New Genomic Mutational and Expressional Data in AML, MDS
Researchers have completed the first comprehensive analysis combining full genomic sequencing and gene-expression profiles of more than 1,300 patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS). The research was presented by Iacobucci et al during the 2019 American Society...
ASH 2019: Oral Azacitidine Improves Survival in Older Patients With AML in First Remission
Treatment with an investigational oral form of azacitidine, CC-486, improved overall survival in older patients with newly diagnosed acute myeloid leukemia (AML) who were in remission following standard induction chemotherapy with or without consolidation therapy, according to a phase III study...
Hematologist/Oncologist Augustine L. Perrotta, DO, Dies at 80
On November 24, hematologist/oncologist Augustine L. Perrotta, DO, died, days before his 81st birthday. Ironically, Dr. Perrotta died of renal cell carcinoma, presenting with metastasis to the spine, a topic about which he had written and lectured extensively. Clinical Professor of Medicine at...
Scott A. Gerber, PhD, Named Inaugural Kenneth E. and Carol L. Weg Distinguished Professor at Dartmouth
Scott A. Gerber, PhD, has been named the Kenneth E. and Carol L. Weg Distinguished Professor at Geisel School of Medicine at Dartmouth College. Dr. Gerber is the first to hold this newly established professorship. Dr. Gerber is Professor of Molecular and Systems Biology and of Biochemistry and...
Thermal Ablation vs Cryotherapy or Loop Excision in Zambian Women Positive for Cervical Precancer
In the pilot phase of an ongoing randomized trial reported in The Lancet Oncology, Partha Basu, MD, and colleagues found that thermal ablation and cryotherapy produced similar treatment success rates in Zambian women positive for cervical precancer on visual inspection with acetic acid. The...
Nivolumab Plus Bevacizumab in Relapsed Ovarian Cancer
In a phase II trial reported in JAMA Oncology, Joyce F. Liu, MD, MPH, and colleagues found evidence of the activity of combined nivolumab and bevacizumab in relapsed ovarian cancer, with activity appearing to be greater in platinum-sensitive disease. Study Details In the trial, 38 women with...
ctDNA and Recurrence Risk After Surgery and Adjuvant Chemotherapy for Stage III Colon Cancer
In a cohort biomarker study reported in JAMA Oncology, Jeanne Tie, MD, and colleagues showed that the circulating tumor DNA (ctDNA)-positive status after surgery and chemotherapy was associated with an increased risk of disease recurrence in patients with stage III colon cancer. Study Details The...
Having Cancer Should Not Make You Homeless
In the spring of 2005, I was launching a new career as a sales consultant for a startup graphics company and wanted to cross off a few essential things on my to-do list, including getting my annual mammogram and physical, before I started my new job. Although I was surprised when I got a call from ...
Study Investigates Quality-of-Life Scores as Prognostic Factors in Patients With Cancer
Patients with cancer who report on their own quality of life can provide information important in predicting the outcome of their disease, according to researchers from the European Organisation for Research and Treatment of Cancer (EORTC). Until recently, reports from clinicians on issues such as...
Zanubrutinib in Previously Treated Mantle Cell Lymphoma
On November 14, 2019, the oral Bruton’s tyrosine kinase (BTK) inhibitor zanubrutinib was granted accelerated approval in the treatment of adult patients with mantle cell lymphoma (MCL) who have received at least one prior therapy.1,2 Supporting Efficacy Data The approval was based on findings from...
Pretreatment Vitamin D Deficiency in Patients Receiving First-Line Treatment for Hodgkin Lymphoma
In a study reported in the Journal of Clinical Oncology, Sven Borchmann, MD, of the German Hodgkin Study Group, University Hospital of Cologne, and colleagues found that pretreatment vitamin D deficiency was associated with significantly poorer progression-free and overall survival in patients...
Global Survey Shows Misperceptions About Lung Cancer Among the General Public
Only one in five people (22%) disagrees with the statement “generally, patients with lung cancer have caused their illness through their lifestyle choices and behaviors,” according to a global, omnibus survey conducted by Ipsos MORI and sponsored by the Lung Ambition Alliance. The results were...
ACCC Project Focuses on Multidisciplinary Care of Cutaneous Squamous Cell Carcinoma
Due to the rarity of advanced cutaneous squamous cell carcinoma, staying current with the latest information on diagnosing, treating, and supporting patients with this diagnosis can be challenging for clinicians who do not often encounter it in practice. To support the multidisciplinary cancer team ...
Alan Hutson, PhD, MA, to Serve on St. Jude Children’s Research Hospital Data Safety Monitoring Board
Alan Hutson, PhD, MA, now holds a 5-year term as a biostatistics expert for the data safety monitoring board at St. Jude Children’s Research Hospital. Dr. Hutson is Chair and Professor of Oncology in the Department of Biostatistics and Bioinformatics at Roswell Park Comprehensive Cancer Center. At ...
Partners HealthCare to Become Mass General Brigham: 5-Year Strategic Plan
Partners HealthCare President and Chief Executive Officer, Anne Klibanski, MD, unveiled a 5-year strategic plan and announced plans for rebranding its health-care system. Partners HealthCare, which serves more than 1.5 million patients and receives nearly $2 billion in research funding annually,...
NCCN Updates Genetic Screening Guidelines
The National Comprehensive Cancer Network® (NCCN®) recently announced publication of the newest genetic risk assessment recommendations for breast, ovarian, and pancreatic cancers. The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Genetic/Familial High-Risk Assessment:...
Studies Show the U.S. Health-Care System Hampered by Waste and Trailing Other High-Income Countries
Recent studies show that at least one-quarter of our nation’s health-care expenditures are being consumed by waste, fraud, and abuse. Moreover, since 2004, annual reports from the Commonwealth Fund have consistently rated the performance of our health-care system last among high-income countries,...
Collaborative Trial to Evaluate Imaging Methods for Women With Dense Breasts
In a new effort to improve early breast cancer detection and reduce false-positive exams in women with dense breasts, the American College of Radiology (ACR), the Breast Cancer Research Foundation (BCRF), and GE Healthcare are partnering to support the Contrast-Enhanced Mammography Imaging...
ASH Releases New Clinical Practice Guidelines on Immune Thrombocytopenia
Earlier this month, the American Society of Hematology (ASH) published new state-of-the-art guidelines on the treatment of immune thrombocytopenia. The guidelines were published in the journal Blood Advances.1 The 2019 ASH Clinical Practice Guidelines on Immune Thrombocytopenia, developed in...
